Your browser doesn't support javascript.
loading
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.
Zozaya, N; Villaseca, J; Abdalla, F; Calleja, M A; Díez-Martín, J L; Estévez, J; García-Sanz, R; Martínez-López, J; Sierra, J; Vera, R; Hidalgo-Vega, A.
Affiliation
  • Zozaya N; Health Economics Department, Weber Economía y Salud, C/Moreto 17, 5D, 28014, Madrid, Spain. neboa.zozaya@weber.org.es.
  • Villaseca J; Department of Quantitative Methods in Economics and Management, University of Las Palmas de Gran Canaria, Las Palmas, Spain. neboa.zozaya@weber.org.es.
  • Abdalla F; Health Economics Department, Weber Economía y Salud, C/Moreto 17, 5D, 28014, Madrid, Spain.
  • Calleja MA; Health Economics Department, Weber Economía y Salud, C/Moreto 17, 5D, 28014, Madrid, Spain.
  • Díez-Martín JL; Pharmacy Department, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Estévez J; Hematology Department, Hospital GU Gregorio Marañón, Gregorio Marañón Health Research Institute, Madrid, Spain.
  • García-Sanz R; Department of Medicine, Complutense University of Madrid, Madrid, Spain.
  • Martínez-López J; The Spanish Society of Health Executives, Sociedad Española de Directivos de La Salud (SEDISA), Madrid, Spain.
  • Sierra J; Hematology Service, CIBERONC, and Salamanca Cancer Research Centre-IBMCC (USAL-CSIC), University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
  • Vera R; Hematology Department, Hospital Universitario, 12 de Octubre, Complutense University of Madrid, CNIO, CIBERONC, Madrid, Spain.
  • Hidalgo-Vega A; Hematology Department and Sant Pau Biomedical Research Institute (IIB-SP), Hospital de la Santa Creu i Sant Pau, Univarsitat Autonoma of Barcelona, Barcelona, Spain.
Clin Transl Oncol ; 24(6): 968-980, 2022 Jun.
Article in En | MEDLINE | ID: mdl-34997475
ABSTRACT
CAR-T cell therapy represents a therapeutic revolution in the prognosis and treatment of patients with certain types of hematological cancer. However, they also pose new challenges in the healthcare, regulatory and financial fields. The aim of the RET-A project was to undertake a strategic reflection on the management of CAR-T therapies within the Spanish National Health System, to agree on recommendations that will help to better deal with the new context introduced by these cell therapies in the present and in the future. This think tank involved 40 key agents and opinion leaders. The experts identified three great challenges for implementing advanced therapies in Spain therapeutic individualisation, with a multidisciplinary approach; acceleration of access times, by minimizing bureaucracy; and increase in the number of centers qualified to manage the CAR-T therapies in the NHS. The experts agreed on the ideal criteria for designating those qualified centers. They also agreed on a comprehensive CAR-T care pathway with the timings and roles which would ideally be involved in each part of the process.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / Receptors, Chimeric Antigen Type of study: Guideline / Prognostic_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Clin Transl Oncol Year: 2022 Document type: Article Affiliation country: España

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / Receptors, Chimeric Antigen Type of study: Guideline / Prognostic_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Clin Transl Oncol Year: 2022 Document type: Article Affiliation country: España